← Leaderboards
Maria V Irazabal
Mayo Clinic Rochester
$3,554,024
Attributed
$3,554,024
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $851.5K · FY2018–24$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,554,024 · 4
By mechanism
R01$2,449,537 · 1
R21$1,004,487 · 2
R56$100,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Peter C. Harris$28,592,075
- Latonya J Hickson$2,371,961
- Jinghua Hu$8,003,740
- Kun Ling$2,464,874
- Jennifer Arroyo$87,620
Others in their field
Other Emerging Leaders on “Kidney”
- Xinhua Li · Nano Terra, Inc.$32,520,955
- Chani Eduard · Precision Bioservices, Inc.$19,909,203
- Robyn Lorraine Woods · Hennepin Healthcare Research Institute$19,109,927
- Barbara Halina Braffett · George Washington University$18,816,779
- Ionut Bebu · George Washington University$18,816,779
- Noel P Burtt · Broad Institute, Inc.$12,561,765
Research focus
KidneyCystic KidneyBilateralAutosomal Dominant Polycystic KidneyDisease ProgressionKidney FailureSeverity Of IllnessImaging TechniquesEnzymesIndexingNovel MarkerUrineFunctional DisorderTherapeutic InterventionBiological MarkersRattusTargeted TreatmentUp-RegulationAnimalsMonitorAdultEvaluationKidney DiseasesCost
Grant awards (10)
Role of homocysteine metabolism, endothelial function and microvascular rarefaction on renal disease severity and progression in ADPKD$593,369
R01 · FY2024 · DK · contact PI
Role of homocysteine metabolism, endothelial function and microvascular rarefaction on renal disease severity and progression in ADPKD$618,303
R01 · FY2023 · DK · contact PI
Role of homocysteine metabolism, endothelial function and microvascular rarefaction on renal disease severity and progression in ADPKD$621,801
R01 · FY2022 · DK · contact PI
Noninvasive evaluation of the intrarenal microvasculature in ADPKD$229,726
R21 · FY2022 · DK · contact PI
Role of homocysteine metabolism, endothelial function and microvascular rarefaction on renal disease severity and progression in ADPKD$616,064
R01 · FY2021 · DK · contact PI
Noninvasive evaluation of the intrarenal microvasculature in ADPKD$189,245
R21 · FY2021 · DK · contact PI
Role of Fumarate and Nrf2 response in the pathogenesis of Autosomal Dominant Polycystic Kidney Disease$198,750
R21 · FY2020 · DK · contact PI
Role of NOX4 and redox environment in Autosomal Dominant Polycystic Kidney Disease$100,000
R56 · FY2020 · DK · contact PI
Role of Fumarate and Nrf2 response in the pathogenesis of Autosomal Dominant Polycystic Kidney Disease$188,016
R21 · FY2019 · DK · contact PI
Role of Fumarate and Nrf2 response in the pathogenesis of Autosomal Dominant Polycystic Kidney Disease$198,750
R21 · FY2018 · DK · contact PI